Leronlimab and maraviroc are monoclonal antibody and small-molecule ligands of CCR5, respectively, which are approved drugs for the treatment of HIV infection and operate by blocking CCR5-tropic HIV entry into CD4+ host cells [69,70]. This evidence concerns the gene CCR5 and HIV infectious disease.